A Phase II Multicenter Study of CAMPATH-1H Antibody in Previously Treated Patients with Nonbulky Non-Hodgkin's Lymphoma

References

• Landis S H, Murray T, Bolden S, et al. Cancer Statistics, 1999. CA Cancer J Clin 1999; 49: 8–31
   PubMed Web of Science ®Google Scholar
• Devesa S S, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992; 52: 5432–5440, suppl
   PubMed Web of Science ®Google Scholar
• Menck H R, Bland K I, Eyre H, et al. Clinical highlights from the National Cancer Data Base, 1998. CA Cancer J Clin 1998; 48: 134–145
   PubMed Web of Science ®Google Scholar
• Multani P, Grossman M. Monoclonal antibody based therapies for hematologic malignancies. J Clin Oncol 1998; 16: 3691–3710
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A, Link B, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for therapy. Nature 1988; 332: 323–327
   PubMed Web of Science ®Google Scholar
• Hale G, Xia M Q, Tighe H P, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35: 118–127
   PubMed Web of Science ®Google Scholar
• Hale G, Dyer M J, Clark M R, et al. Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody Campath-1H. Lancet 1988; 2: 1394–1399
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer M J, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567–1574
   PubMed Web of Science ®Google Scholar
• Pawson R, Dyer M J, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15: 2667–2672
   PubMed Web of Science ®Google Scholar
• Tang S C, Hewitt K, Reis M, et al. Immunosuppressive toxicity of CAMPATH-1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymph 1996; 24: 93–101
   PubMed Web of Science ®Google Scholar
• Dyer M J, Hale G, Marcus R, et al. Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1H monoclonal antibodies. Leuk Lymph 1990; 2: 179–193
   PubMed Web of Science ®Google Scholar
• DeNully Brown P, Hansen M M, Nissen N I. Campath IH-a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia [Danish]. Ugerskrift for Laeger 1997; 159: 4389–4393
   PubMedGoogle Scholar
• Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. J Clin Oncol 1998; 16: 3257–3263
   PubMed Web of Science ®Google Scholar
• Clendeninn N, Nethersell A, Scott J, et al. Phase I/II trials of CAMPATH-1H, a humanized anti-lymphocyte monoclonal antibody in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Blood 1992; 80(suppl 1)158a, abstr
   Google Scholar
• Willemze R, Richel D J, Falklenburg J H, et al. In vivo use of CAMPATH-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. Bone Marrow Transplant 1992; 9: 255–261
   PubMed Web of Science ®Google Scholar
• Hertenstein B, Arseniev L, Novotny J, et al. Prevention of graft-versus-host disease by transplantation of allogeneic CD34+ blood cells additionally T-cell depleted with CAMPATH-1H. Blood 1996; 88(suppl 1)262b, abstr
   Google Scholar
• Treleaven J, Powles R, Singhal S, et al. Autografting with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia. Blood 1996; 88(suppl 1)255a, abstr
   Google Scholar
• Cobbold S P, Hale G, Clark M R, et al. Purging in auto-and allo-grafts: monoclonal antibodies which use human complement and other natural effector mechanisms. Progress in Clinical & Biological Research 1990; 333: 139–151
   PubMedGoogle Scholar
• Schnitzer T J, Yocum D E, Michalska M, et al. Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes. J Rheumatol 1997; 24: 1031–1036
   PubMed Web of Science ®Google Scholar
• Moreau T, Coles A, Wing M, et al. CAMPATH-1H in multiple sclerosis. Multiple Sclerosis 1996; 1: 357–65
   PubMedGoogle Scholar
• Killick S B, Marsh J C, Hale G, et al. Sustained remission of severe resistant autoimmune neutropenia with CAMPATH-1H. British Journal of Hematology 1997; 97: 306–308
   PubMed Web of Science ®Google Scholar
• Lim S H, Hale G, Marcus R E, et al. CAMPATH-1H monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. British Journal of Hematology 1993; 84: 542–544
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Grillo-Lopez A J, White C A, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17(1)268–276
   PubMed Web of Science ®Google Scholar
• Salisbury J, Rapson N, Codd J, et al. Immunohisto-chemical analysis of CD52 antigen expression in non-Hogkin's lymphoma. J Clin Pathol 1994; 47: 313–317
   PubMed Web of Science ®Google Scholar